The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved Peptides Might Be Making a Comeback In 2023, the FDA restricted 19 peptides from compounding pharmacies. Now, regulators are reviewing a possible reversal, which could allow 14 of those peptides to The Pharmacology of Longevity: Peptide Edition (Part 1) FDA takes first step in possible reversal of ban on some peptides The Washington Post